Please assess the completion status of the following clinical trial:

Trial Title: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* salmon \& Durie stage II/III A or B~* previous lenalidomide refractory disease~* patient commits to pregnancy prevention programme~Exclusion Criteria:~* non-secretory myeloma~* known hypersensitivity to lenalidomide~* inadequate marrow reserve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- lenalidomide, endoxan, prednisone (Type: EXPERIMENTAL): lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).